In addition, Drug Product adjusted contract margins for the second quarter of 2015 risen to 17 percent in comparison to -14 percent for the same period of 2014, driven by the additions of the OsoBio and Glasgow businesses and by increased capability utilization. For the initial half of 2015, Drug Product contract income improved $34.9 million to $39.9 million from $5.0 million in 2014, due mainly to the addition of $24.5 million in revenue from OsoBio, $7.4 million in revenue from Glasgow, and a 58 percent upsurge in organic revenue. Medication Product adjusted gross margins improved to 18 percent in 2015 from -17 percent in 2014, due to the additions of Glasgow and OsoBio and increased capability utilization. Liquidity and Capital Resources At June 30, 2015, AMRI had money, money equivalents and restricted cash of $45.6 million, compared to $32.2 million at March 31, 2015.The study was authorized by the ethics committee at each organization, and all of the patients provided written informed consent. Genomic DNA was obtained from bone marrow mononuclear cells, peripheral-blood granulocytes, or whole-blood samples. Germline control DNA was obtained from immunomagnetically purified circulating T cells. Whole-Exome Sequencing Whole-exome sequencing was performed in six sufferers with primary myelofibrosis who didn’t have mutations in JAK2 or MPL. Genomic DNA libraries had been generated from peripheral-blood granulocyte DNA and matched CD3+ T-lymphocyte DNA by using the NEBNext DNA Sample Prep Reagent arranged .